Regular ArticleAntiplatelet activity of SEMOTIADIL (cas 116476-13-2) fumarate

Add time:08/13/2019    Source:sciencedirect.com

Calcium antagonists are known to exert antiplatelet activity. SEMOTIADIL (cas 116476-13-2) fumarate (SD-3211), a new benzothiazine, was therefore examined for its antiplatelet activity. The inhibitory activity on adenosine diphosphate (ADP)-, collagen-, arachidonic acid (AA)-, and platelet activating factor (PAF)-induced platelet aggregation after the 1-, 30-, 60- and 120-min incubation at concentrations ranging from 1×10−3, 1×10−4, 1×10−5, 1×10−6 and 1×10−7 was examined. The data were compared with those using diltiazem, nifedipine and amlodipine under identical conditions in blood from eight healthy volunteers (four males, four females; aged 23–36 years) and eight hypertensive patients (four males, four females; aged 31–46 years). Semotiadil showed a dose-dependent inhibition of platelet aggregation in vitro with all the agents examined. Using the various aggregation-inducing agents, the dose-dependent inhibitory action was comparable for all the compounds tested. The antiaggregatory potency was in the order diltiazem, semotiadil, amlodipine and nifedipine. The incubation period did not significantly affect the antiaggregatory effect. No difference between platelets derived from healthy volunteers and hypertensive patients was noted. These findings indicate potent antiplatelet activity of the new calcium antagonist semotiadil.

We also recommend Trading Suppliers and Manufacturers of SEMOTIADIL (cas 116476-13-2). Pls Click Website Link as below: cas 116476-13-2 suppliers

Prev:On the influence of the heterocyclic ring substituents on the structure of dimethylthallium pyrimidine-2-thionato complexes. Crystal structure of dimethyl-(4-trifluoromethylpyrimidine-2-thionate)thallium(III): a compound with intermolecular C–H ⋯ π interactions
Next:SEMOTIADIL (cas 116476-13-2) improves survival of rats with monocrotaline-induced pulmonary hypertension: comparison with diltiazem)